Advertisement
UK markets closed

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     

  • CRUDE OIL

    82.66
    -0.70 (-0.84%)
     

  • GOLD FUTURES

    2,338.60
    -3.50 (-0.15%)
     

  • DOW

    38,363.72
    -139.97 (-0.36%)
     

  • Bitcoin GBP

    52,016.61
    -1,640.27 (-3.06%)
     

  • CMC Crypto 200

    1,399.10
    -25.00 (-1.76%)
     

  • NASDAQ Composite

    15,668.64
    -28.00 (-0.18%)
     

  • UK FTSE All Share

    4,374.06
    -4.69 (-0.11%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

Could AstraZeneca's Nasal COVID Vaccine Development Zap Altimmune's Prospects?

Keith Speights and Brian Orelli, PhD, The Motley Fool
·4-min read

Altimmune (NASDAQ: ALT) began clinical testing of its intranasal COVID-19 vaccine candidate earlier this year. The University of Oxford recently began testing a nasal-spray version of the COVID-19 vaccine that it developed with big drugmaker AstraZeneca (NASDAQ: AZN). In this Motley Fool Live video recorded on March 31, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not an intranasal COVID-19 vaccine from AstraZeneca could zap Altimmune's prospects.

Continue reading